2.Three Cases of Mirtazapine Induced Akathisia.
Seung Hwan LEE ; Min NAM ; Young Cho CHUNG
Journal of the Korean Society of Biological Psychiatry 2001;8(1):162-166
The mirtazapine is a relatively new antidepressant that has noradrenergic and specific serotonin antagonist action(NaSSAs). This has been known as one of the most safest drugs because of its few side effects. Until now, there have been only one case report that mirtazapine causes a EPS side effect(restless leg syndrome). But the peculiar mechanism of this drug makes it impossible to explain the exact reasons why the mirtazapine could induce EPS symptoms. Authors obseved three cases of mirtazapine indeced akathisia. We could not explain the phenomenon the other way except akathisia. So here we presents the three case of mirtazapine induced akathisia and a few possible hypothesis of this phenomenon.
Leg
;
Psychomotor Agitation*
;
Serotonin
3.Management Dilemma in Olanzapine Induced Restlessness and Cramps in Legs.
Clinical Psychopharmacology and Neuroscience 2017;15(1):87-88
No abstract available.
Leg*
;
Muscle Cramp*
;
Psychomotor Agitation*
4.The Effect of Cyproheptadine Treatment in Neuroleptic Induced Akathisia.
Dong Seon CHUNG ; In Joon PARK ; Young Joon KWON ; Hee Yeon JUNG ; Sun Ho HAN
Journal of Korean Neuropsychiatric Association 1997;36(5):935-941
OBJECTIVE: Neuroleptic Induced Akathisia(NIA) often occurs in neuroleptic treated patients. Cyproheptadine, an antiserotonergic agent, was used to treat neuroleptic induced akathisia. METHOD: In an open trial 21 neuroleptic-treated patients with akathisia were administrated Cyproheptadine(16mg/day) over 4 days. Assessment of akathisia was evaluated using Barnes' rating scale(BAS) for neuroleptic induced akathisia. The degree of depression and psychosis were assessed by brief psychiatric rating scale(BFRS) and Hamilton rating scale for depression(HAM-D). RESULT: Most patients(20 of 21) with neuroleptic induced akathisia(NIA) showed improvement under the treatment of cyproheptadine. There was no aggravation of psychosis or depression during the treatment. Symptoms of akathisia aggravated when cyproheptadine was discontinued. CONCLUSION: Cyproheptadine may be useful in the treatment of neuroleptic induced akathisia(NIA).
Cyproheptadine*
;
Depression
;
Humans
;
Psychomotor Agitation*
;
Psychotic Disorders
5.A Study on Depression in College Students.
Jong Bum LEE ; Byung Tak PARK ; Sung Douk CHEUNG ; Jong Hak CHUNG
Yeungnam University Journal of Medicine 1985;2(1):123-132
The authors studied depression in 5,869 college students (male: 3,893, female: 1,976) using Zung's Self-Rating Depression Scale (SDS). The results are as follows: 1) Female college students showed significantly higher total depression scores than male college students (p<0.001). 2) The items of confusion, indecisiveness, and psychomotor retardation were scored higher in both groups and the items of suicidal rumination, psychomotor agitation, constipation and tachycardia were scored lower in both groups. 3) 18.2% of male college students showed rather serious depression level of score 50 or higher, while 33.1% of female college students showed the same scores. 4) The psychosocial factors relating to pessimistic views to past, present & future self-images showed significantly high depression scores. 5) The depression items of fatigue, anxiousness, tachycardia, apprehension, fear, and body aches & pain were correlated significantly over 0.40 of correlation coefficient.
Constipation
;
Depression*
;
Fatigue
;
Female
;
Humans
;
Male
;
Psychology
;
Psychomotor Agitation
;
Tachycardia
6.Development of the Korean Form of Zung's Self-Rating Depression Scale.
Yeungnam University Journal of Medicine 1995;12(2):292-305
This study was carried out to develop a Korean language version of Zung's self-rating depression scale (SDS). The subjects consisted of 173 males and 161 females drawn from various groups of the general population by a cluster of sampling methods. In order to analyze the data on depression scores, Pearson's product moment correlation coefficient method was carried .out, as well as reliability and factor analysis, by the SPSS/PC+ program. The results obtained were as follows: The mean average of the total depression scores were 40.60. 8.66 for the subjects. Thirty-seven subjects (11.1%) showed high depression scores of 50 or over. Test-retest reliability(coefficient r=0.82, p <0.001), internal consistency(coefficient r=0.84, p <0.001) were satisfactory. Factor analysis using oblique technique rotation yielded five factors. The items of confusion, indecisiveness, decreased libido, diurnal variation, and psychomotor retardation were scored higher by the subjects. The items of suicidal rumination, psychomotor agitation, constipation, irritability, and weight loss were scored lower.
Constipation
;
Depression*
;
Female
;
Humans
;
Libido
;
Male
;
Psychomotor Agitation
;
Weight Loss
7.Comparison of Amisulpride and Risperidone in the Treatment of Psychosis in Patients with Dementia of the Alzheimer's Type.
Hyun Kook LIM ; Su Jin KIM ; Chi Un PAE ; Chul LEE ; Chang Uk LEE
Journal of Korean Geriatric Psychiatry 2007;11(1):35-39
This study compared the effectiveness and tolerability of amisulpride and risperidone in patients with psychosis associated with dementia of the Alzheimer's type (DAT). This 8-week open label study randomized 72 patients with DAT associated psychosis either to amisulpride (n=36) and risperidone (n=36). The effectiveness of the treatments was assessed with the Korean version of Neuropsychiatry Inventory (K-NPI) psychosis subscale and total K-NPI and the Clinical Global Impression-Severity of Illness (CGI-S) scale. The Simpson-Angus Rating Scale, the Barnes Akathisia Rating Scale and the Abnormal Involuntary Movement Scale were used for the assessment of side effects. The K-NPI psychosis subscale, total K-NPI and CGI-S scores were significantly decreased over time in both treatment groups without any significant group difference and time by the group interaction effect. There were no serious adverse events in both groups. This study showed that either amisulpride or risperidone would be effective and tolerable for treating psychotic symptom associated with DAT. Adequately powered studies with a head-to-head comparison design will be mandatory to draw any definite conclusion.
Dementia*
;
Dyskinesias
;
Humans
;
Neuropsychiatry
;
Psychomotor Agitation
;
Psychotic Disorders*
;
Risperidone*
8.Add-On Therapy of Quetiapine for Bipolar Disorder: A 6 Month, Prospective Trial.
Chi Un PAE ; Tae Suk KIM ; Young Ji LEE ; Jung Jin KIM ; Soo Jung LEE ; Chang Uk LEE ; Chul LEE ; In Ho PAIK
Korean Journal of Psychopharmacology 2005;16(4):279-284
OBJECTIVES: This study was conducted to evaluate the overall effectiveness and tolerability of adjunctive quetiapine in the long-term treatment of bipolar disorder as a continuation therapy. METHODS: Twenty-three bipolar I patients participated and required to have quetiapine add-on treatment in combination with existing or new mood stabilizers. Clinical assessment was carried out using Young Mania Rating Scale (YMRS), Clinical Global Impression (CGI), Hamilton Depression Rating Scale-17 item, Simpson-Angus Rating Scale and Barnes Akathisia Rating Scale at baseline, 1, 4, 12 and 24 weeks. RESULTS: The YMRS and CGI decreased significantly from baseline to endpoint by 89.7% and 78.3%, respectively (p<0.0001 ; p<0.0001). Twenty-two patients exhibited at least 50% improvement on YMRS score by the end of the study. CONCLUSION: This study suggests that quetiapine may hold a promise as an adjunct in the long-term treatment of bipolar disorder.
Bipolar Disorder*
;
Depression
;
Humans
;
Prospective Studies*
;
Psychomotor Agitation
;
Quetiapine Fumarate
9.A Clinical Study on Antihypertensive Effects of Aldactazide (Spironolactone+Hydrochlorothiazide).
Myoung Mook LEE ; Seong Yun KIM ; Jeong Eui PARK ; Young Woo LEE ; Sung Ho LEE
Korean Circulation Journal 1977;7(2):27-33
The antihypertensive effects fo aldactazide and serum electrolytes changes before and after treatment with aldactazide were observed. The followings were obtained: 1. Results of antihypertensive therapy with aldactazide in 23 hypertensive patients revealed good effects in 52.17%, fair in 26.09%, poor in 8.7%, and failure in 13.04% of cases. In 78.26% of cases, good or fair control of blood pressure was obtained. 2. Daily doses of aldactazide ranged from 25mg to 50mg depending upon the level of blood pressure. The antihypertensive effects were appeared after average 11 days of administration. 3. The side effects during treatment with aldactazide were dizziness, weakness, indigestion, headache, and restlessness in 26.28% of cases (6 of 23 cases). 4. No significant changes in serum Na and K values were observed before and after treatment with aldactazide for average 23 days.
Blood Pressure
;
Dizziness
;
Dyspepsia
;
Electrolytes
;
Headache
;
Humans
;
Psychomotor Agitation
10.Differences in Clinical Manifestations between Bipolar I and Bipolar II Disorders in Korean Population.
Ji Hyun BAEK ; Dong Yeon PARK ; Hae Jung PARK ; Jung Mi CHOI ; Ji Sun CHOI ; Ji Hye NOH ; Dongsoo LEE ; Kyung Sue HONG
Journal of Korean Neuropsychiatric Association 2009;48(4):232-239
OBJECTIVES : Whether bipolar II disorder (BP-II) is simply a milder form of bipolar I disorder (BP-I) or a valid diagnostic category that could be separated from BP-I, is an issue still under consideration. Investigations exploring differential clinical and biological features of the two conditions are needed to resolve the controversies. This study aimed to obtain a comprehensive view of differences in clinical course and symptoms characteristics between BP-I and BP-II. METHODS : 44 BP-I and 26 BP-II patients were assessed using the Diagnostic Interview for Genetic Studies (DIGS), Korean version. Demographic data, age at onset, number of (hypo) manic/ depressive episodes, the duration of illness, polarity at onset, seasonality, rapid cycling, atypical depression and symptom profiles of each episode were evaluated. RESULTS : BP-II patients experienced depressive episodes more frequently than BP-I patients after illness onset (U=240.5, p=0.008). More BP-II patients showed seasonality (34.9% vs. 61.5%) and a rapid cycling course (4.5% vs. 18.2%). When comparing symptom profiles of manic/hypomanic episodes, irritable mood, decreased sleep need, inattention, reckless behavior, arrogant/provocative attitude and frequent outbursts of anger were less encountered in BP-II patients. In depressive episodes, leaden paralysis and psychomotor agitation were more frequently observed in BP-II patients. There was no significant difference between the two groups in psychotic symptoms of depressive episode. CONCLUSION : BP-I and BP-II disorders showed differences in clinical courses and symptom profiles. BP-II disorder seems to be less severe than BP-I disorder with regard to the intensity of manic symptoms, but more severe with respect to frequencies of depressive episodes. These results provide additional evidence supporting the distinction of BP-I and BP-II as separate diagnos-tic categories that might have different genetic profiles and/or biological mechanisms.
Anger
;
Depression
;
Humans
;
Irritable Mood
;
Paralysis
;
Psychomotor Agitation
;
Seasons